Market Scenario

Owing to favorable factors, the veterinary vaccines market in the Middle East and Africa is striving to reach around USD 550.84 million during forecast period (2017-2022) from USD 365 million in 2015, reports Market Research Future (MRFR). The market can experience a robust CAGR of 7.1% over the forecast period. The Middle East and Africa veterinary vaccine market is a progressing market, owing to unmet needs of a huge number of unvaccinated animals, growing demand for animal products especially dairy and meat, and rise in the prevalence of animal diseases such as foot and mouth disease.

Environmental conditions of Africa which increase chances of diseases, presence of wild animals near human settlements which can propagate transmission, growth in the number of pet owners, and entry of China in the vaccine manufacturing market may impact the growth of the market positively. Moreover, this market is expected to be lucrative with profitable investments from both government and non-government players. Increasing number of pet owners and their shifting focus towards healthy animal practices are some other factors that have spurred the surge of the market in these regions.

However, tough competition from the European dairy and meat industry, adverse effects of vaccination, and lack of awareness undermine the otherwise growing veterinary vaccines market. On the other hand, latest trends in the vaccine market including growing emphasis on technology and the rise of recombinant DNA vaccines can act as catalyst for the market in the Middle East and Africa.

Market Segmentation

The Middle East and Africa veterinary vaccines market has been segmented on the basis of technology, disease indication, composition, and animal type.

By technology, the market is segmented into attenuated, inactivated, toxoid, conjugate, subunit and recombinant DNA. Recombinant DNA technology is a highly popular segment which combines safety, purity, potency, and efficacy in its vaccines. Its positive features include non-exposure to the pathogen, lack of need for adjuvants, and stability which allows vaccines to remain viable at ambient temperatures. 

On the basis of disease indication, the market is segmented into foot & mouth disease, parvovirus, distemper, reproductive & respiratory syndrome, and others. Foot and mouth disease results in economic losses for farmers and in turn the country, as infected cattle lose weight and stop lactating. This can also affect export trade activities of certain agricultural products. These factors can lead to heavy demand for veterinary vaccines, thus resulting in immense segment growth.

The market is segmented on the basis of composition into mono vaccine and combination vaccines. Combination vaccines reduce the required number of injections which reduce trauma and has been found to lead to higher rates of compliance with combination vaccination schedules. Also, increased vaccine coverage is observed with the use of combination vaccines.

By animal type, market is segmented into poultry, bovine, porcine, companion and other.

Regional Analysis of the Middle East and Africa Veterinary Vaccines Market

UAE is the largest market for veterinary vaccines in the entire Middle East and Africa veterinary vaccines market trailed by Egypt. Africa’s market especially the sub-Saharan regions, is the fastest growing market due to huge unmet medical needs. Increasing awareness for food security coupled with increasing investment by government agencies in this region help thrust the market to higher dimensions.

Moreover, rising demand for milk, eggs, meat, and animal protein along with investment by the government for veterinary vaccines would present the market with massive opportunity in the Middle East and Africa. Heavy economic losses in Africa due to affected livestock, threat to farmer livelihoods, and food concerns leads to heavy demand for veterinary vaccines, can induce market demand.

Competitive Landscape

Some of the key players in the veterinary vaccine market are Zoetis Inc., Elanco Animal Health, Bayer AG, Indian Immunologicals Limited, Boehringer Ingelheim GmbH, Merck Animal Health, MSD Animal Health, and others.

In June 2018, MSD Animal Health and Vinovo formed a partnership, with the agreement combining broad vaccine portfolio with novel delivery system of both the companies respectively, to protect against highly infectious poultry diseases. It will provide a new standard for safe and effective ovo vaccination, thereby improving bird welfare, reducing vaccine reactions, and providing greater protection for chickens. It will protect the poultry against highly infectious diseases. Continuous development of veterinary vaccines by companies in the market to safeguard animals is fuelling the market and increasing its demand in the regions of Middle East and Africa.